105
Participants
Start Date
May 4, 2016
Primary Completion Date
November 2, 2022
Study Completion Date
August 1, 2025
MEK162
• MEK162 is currently supplied as film-coated tablets in dose strength of 15 mg. The film-coated tablets consist of MEK162 drug substance, lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, and a commercial film coating. The original tablets are yellow to dark yellow capsule-shaped
New York University, New York
Children's National Heath Systems, Washington D.C.
Johns Hopkins University, Baltimore
Children's Healthcare of Atlanta, Atlanta
Nicklaus Children's Hospital, Miami
Children's Hospital of Alabama, Birmingham
Children's Hospitals and Clinics of Minnesota-Minneapolis, Minneapolis
Washington University School of Medicine, St Louis
University of Texas Southwestern Medical, Dallas
Texas Children's Hospital, Houston
Children's Hospital of Colorado, Aurora
Children's Hospital Los Angeles, Los Angeles
Oregon Health and Science University, Portland
Seattle Children's Hospital, Seattle
Dana Farber Cancer Institute, Boston
Dana-Farber Cancer Institute
OTHER
Children's Hospital Los Angeles
OTHER